nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

04.03.2022

The Role of Autoantibody Testing in Modern Personalized Medicine

verfasst von: Cristiane Kayser, Lívia Almeida Dutra, Edgard Torres dos Reis-Neto, Charlles Heldan de Moura Castro, Marvin J. Fritzler, Luis Eduardo C. Andrade

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Personalized medicine (PM) aims individualized approach to prevention, diagnosis, and treatment. Precision Medicine applies the paradigm of PM by defining groups of individuals with akin characteristics. Often the two terms have been used interchangeably. The quest for PM has been advancing for centuries as traditional nosology classification defines groups of clinical conditions with relatively similar prognoses and treatment options. However, any individual is characterized by a unique set of multiple characteristics and therefore the achievement of PM implies the determination of myriad demographic, epidemiological, clinical, laboratory, and imaging parameters. The accelerated identification of numerous biological variables associated with diverse health conditions contributes to the fulfillment of one of the pre-requisites for PM. The advent of multiplex analytical platforms contributes to the determination of thousands of biological parameters using minute amounts of serum or other biological matrixes. Finally, big data analysis and machine learning contribute to the processing and integration of the multiplexed data at the individual level, allowing for the personalized definition of susceptibility, diagnosis, prognosis, prevention, and treatment. Autoantibodies are traditional biomarkers for autoimmune diseases and can contribute to PM in many aspects, including identification of individuals at risk, early diagnosis, disease sub-phenotyping, definition of prognosis, and treatment, as well as monitoring disease activity. Herein we address how autoantibodies can promote PM in autoimmune diseases using the examples of systemic lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis, Sjögren syndrome, systemic sclerosis, idiopathic inflammatory myopathies, autoimmune hepatitis, primary biliary cholangitis, and autoimmune neurologic diseases.

Auffray C, Charron D, Hood L (2010) Predictive, preventive, personalized and participatory medicine: Back to the future. Genome Med 2:57CrossRef

Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O et al (2015) A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev 14:75–79CrossRef

Fava A, Petri M (2019) Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun 96:1–13CrossRef

Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39:257–268CrossRef

Vilar MJ, Sato EI (2002) Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus 11:528–532CrossRef

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151–1159CrossRef

Fernandez SA, Lobo AZ, Oliveira ZN, Fukumori LM, Périgo AM, Rivitti EA (2003) Prevalence of antinuclear autoantibodies in the serum of normal blood donors. Rev Hosp Clin Fac Med Sao Paulo. 58:315–319

Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191–200CrossRef

Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC et al (2020) Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol 72:1026–1035CrossRef

10.

Dellavance A, Gabriel AJ, Nuccitelli B, Taliberti T, von Mühlen C, Bichara CDA et al (2009) Third Brazilian consensus for autoantibody research in HEp-2 cells (FAN). Recommendations for standardization of the autoantibody screening assay in HEp-2 cells, quality control and clinical associations. Rev Bras Rheumatol 49:89–109

11.

Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ et al (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879–889CrossRef

12.

Chan EKL, Damoiseaux J, Carballo OG, Conrad K, Cruvinel WM, Francescantonio PLC et al (2015) Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol 6:412CrossRef

13.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT et al (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61:1168–1178CrossRef

14.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930CrossRef

15.

Prado MS, Dellavance A, Rodrigues SH, Marvulle V, Andrade LEC (2020) Changes in the result of antinuclear antibody immunofluorescence assay on HEp-2 cells reflect disease activity status in systemic lupus erythematosus. Clin Chem Lab Med 58:1271–1281CrossRef

16.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J et al (2018) Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. Arthritis Care Res (Hoboken) 71:893–902

17.

Quismorio F, Torralba K (2013) Clinical application of serologic tests, serum protein abnormalities, and other clinical laboratory test in SLE. In: Wallace D, Hahn B (eds) Dubois’ lupus erythematosus and related syndromes, 8th edn. Elsevier Saunders, Philadelphia, PA, pp 526–540CrossRef

18.

Brito-Zerón P, Izmirly P, Ramos-Casals M, Buyon J, Khamashta M (2015) The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 11:301–312CrossRef

19.

Wahren-Herlenius M, Sonesson SE, Clowse ME (2012) Neonatal lupus erythematosus. In: Wallace D, Hahn B (eds) Dubois’ lupus erythematosus and related syndromes, 8th edn. Saunders, Philadelphia, pp 464–472

20.

Sammaritano L, Bermas B, Chakravarty E, Chambers C, Clowse M, Lockshin M et al (2020) 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72:529–556CrossRef

21.

Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G et al (2004) Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum 50:1248–1252CrossRef

22.

Lazzerini PE, Capecchi PL, Guideri F, Bellisai F, Selvi E, Acampa M et al (2007) Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro/SSA and connective tissue disease. Am J Cardiol 100:1029–1034CrossRef

23.

Satoh M, Fritzler MF, Chan EKL (2020) Antihistone and antispliceosome antibodies. In: Tsokos GC (ed) Lupus erythematosus: basic, applied and clinical aspects, 1st edn. Academic Press, New York, pp 237–247

24.

Furtado R, Pucinelli M, Cristo V, Andrade L, Sato E (2002) Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud’s phenomenon in SLE patients. Lupus 11:35–41CrossRef

25.

Migliorini P, Baldini C, Rocchi V, Bombardieri S (2005) Anti-Sm and anti-RNP antibodies. Autoimmunity 38:47–54CrossRef

26.

Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I et al (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: Significant factors associated with lupus nephritis. Ann Rheum Dis 62:556–560CrossRef

27.

van Vollenhoven RF, Fly M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958–967CrossRef

28.

Tseng C, Buyon J, Kim M, Belmont H, Mackay M, Diamond B et al (2006) The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:3623–3632CrossRef

29.

Hung W, Chen Y, Lan J, Chen H, Chen Y, Chen D et al (2011) Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis. Lupus 20:1404–1410CrossRef

30.

Ng K, Manson J, Rahman A, Isenberg D (2006) Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 55:900–904CrossRef

31.

Sui M, Sui M, Lin Q, Xu Z, Han X, Xie R et al (2013) Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis. J Clin Immunol 33:378–387CrossRef

32.

Stinton LM, Barr SG, Tibbles LA, Yilmaz S, Sar A, Benedikttson H et al (2007) Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus 16:394–400CrossRef

33.

Sinico R, Radice A, Ikehata M, Giammarresi G, Corace C, Arrigo G et al (2005) Anti-C1q autoantibodies in lupus nephritis: Prevalence and clinical significance. Ann New York Acad of Sci 1050:193–200CrossRef

34.

Siegert C, Daha M, Westedt ML, van der Voort E, Breedveld F (1991) IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 18:230–234

35.

Orbai A-M, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcón GS et al (2015) Anti- C1q antibodies in systemic lupus erythematosus. Lupus 24:42–49CrossRef

36.

Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J et al (2011) Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: Predictive value for renal flares. Lupus 20:28–34CrossRef

37.

Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A et al (2009) Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 68:234–237CrossRef

38.

Choi M, FitzPatrick R, Buhler K, Mahler M, Fritzler M (2020) A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev 19:102463

39.

Haddouk S, Marzouk S, Jallouli M, Fourati H, Frigui M, Hmida Y et al (2009) Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 48:953–957CrossRef

40.

Bonfa E, Golombek S, Kaufman L, Skelly S, Weissbach H, Brot N et al (1987) Association between lupus psychosis and anti-ribosomal P protein antibodies. New Eng J Med 317:265–271CrossRef

41.

do Nascimento A, Viana VDS, Testagossa LDA, Leon E, Borba E, Barros R et al (2006) Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum 54:1568–1572

42.

Macedo P, Borba E, Viana VDS, Leon E, Testagossa L, Barros R et al (2011) Antibodies to ribosomal P proteins in lupus nephritis: is a surrogate marker for a better renal survival? Autoimmun Rev 10:126–130

43.

Calich A, Viana V, Cancado E, Tustumi F, Terrabuio D, Leon E et al (2013) Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis. Liver Int 336:909–913CrossRef

44.

Tektonidou M, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos P, Moutsopoulos H (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies:Pprevalence, clinical associations, and long-term outcome. Arthritis Rheum 50:2569–2579CrossRef

45.

Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA et al (2015) Haematological manifestations of lupus. Lupus Sci Med 2:e000078

46.

Stegert M, Bock M, Trendelenburg M (2015) Clinical presentation of human C1q deficiency: How much of a lupus? Mol Immunol 67:3–11CrossRef

47.

Araujo MNT, Silva NP, Andrade LEC, Sato EI, Gerbase-DeLima M, Leser PG (1997) C2 deficiency in blood donors and lupus patients: prevalence, clinical characteristics and HLA-associations in the Brazilian population. Lupus 6:462–466CrossRef

48.

Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B et al (2007) Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): Low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 80:1037–1054CrossRef

49.

Pereira KMC, Perazzio S, Faria AGA, Moreira ES, Santos VC, Grecco M et al (2019) Impact of C4, C4A and C4B gene copy number variation in the susceptibility, phenotype and progression of systemic lupus erythematosus. Adv Rheumatol 59:36–42CrossRef

50.

Hughes G (1983) Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 287:1088–1089CrossRef

51.

McNeil H, Simpson R, Chesterman C, Krilis S (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H). Proc Nati Acad Sci U S A 87:4120–4124CrossRef

52.

Groot P, Urbanus R (2012) The significance of autoantibodies against β2-glycoprotein I. Blood 120:266–274CrossRef

53.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R et al (2006) International consensus statement on an update of the classification criteria for a definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRef

54.

Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML et al (2020) Development of new international antiphospholipid syndrome classification criteria phase I/II Report: Generation and reduction of candidate criteria. Arthritis Care Res (Hoboken). Online ahead of print: https://doi.org/10.1002/acr.24520

55.

Urbanus R, Siegerink B, Roest M, Rosendaal F, de Groot P, Algra A (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 8:998–1005CrossRef

56.

Devreese KMJ (2020) Testing for antiphospholipid antibodies: advances and best practices. Int J Lab Hematol 42(Suppl 1):49–58CrossRef

57.

Jayakody Arachchillage D, Greaves M (2014) The checked history of the antiphospholipid syndrome. British J Haematol 165:609–617CrossRef

58.

Reynaud Q, Lega J, Mismetti P, Chapelle C, Wahl D, Cathébras P et al (2014) Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 13:595–608CrossRef

59.

Schouwers SM, Delanghe JR, Devreese KM (2010) Lupus anticoagulant (LAC) testing in patients with inflammatory status: Does C-reactive protein interfere with LAC test results? Thromb Res 125:102–104CrossRef

60.

Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta M (2013) Seronegative antiphospholipid syndrome. Rheumatology (Oxford) 52:1358–1367CrossRef

61.

Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limón P, Martínez-Martínez L, Jatwani S et al (2013) Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65:3186–3193CrossRef

62.

Morales J, Martinez-Flores J, Serrano M, Castro M, Alfaro F, García F et al (2015) Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I. J Am Soc Nephrol (JASN) 26:735–745CrossRef

63.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta M, Bertolaccini M (2014) Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 111:354–364CrossRef

64.

Litvinova E, Darnige L, Kirilovsky A, Burnel Y, Luna G, Dragon-Durey M (2018) Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol 9:2971CrossRef

65.

Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K et al (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64:504–512CrossRef

66.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta M, Bertolaccini M (2013) GAPSS: The global anti-phospholipid syndrome score. Rheumatology (Oxford) 52:1397–1403CrossRef

67.

Radin M, Cecchi I, Roccatello D, Meroni P, Sciascia S (2018) Prevalence and thrombotic risk assessment of anti-β2 Glycoprotein I domain I antibodies: a systematic review. Semin Thromb Hemost 44:466–474CrossRef

68.

Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E et al (2015) Antiphospholipid syndrome: Antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 13:782–787CrossRef

69.

Nakamura H, Oku K, Amengual O, Ohmura K, Fujieda Y, Kato M et al (2018) First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: The combination of anti-β 2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin complex antibodies tests. Arthritis Care Res (Hoboken) 70:627–634CrossRef

70.

Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Ninety F, Iliceto S (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93:1147–1152CrossRef

71.

Ruffatti A, Calligaro A, Hoxha A, Trevisanuto D, Ruffatti A, Gervasi M et al (2010) Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 62:302–307CrossRef

72.

Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou M, Ugarte A et al (2019) The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum 49:464–468CrossRef

73.

Burgos-Vargas R, Catoggio LJ, Galarza-Maldonado C, Ostojich K, Cardiel MH (2013) Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatol Clin 9:106–112CrossRef

74.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS et al (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001CrossRef

75.

Greenblatt HK, Kim HA, Bettner LF, Deane KD (2020) Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Opin Rheumatol 32:289–296CrossRef

76.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699CrossRef

77.

Wu CY, Yang HY, Luo SF, Lai JH (2021) From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. Int J Mol Sci 22:686CrossRef

78.

Aletaha D (2020) Precision medicine and management of rheumatoid arthritis. J Autoimmun 110:102405

79.

Tarn JR, Lendrem DW, Isaacs JD (2020) In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis. Expert Rev Clin Immunol 16:621–630CrossRef

80.

Bettner LF, Peterson RA, Bergstedt DT, Kelmenson LB, Demoruelle MK, Mikuls TR et al (2021) Combinations of anticyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years. ACR Open Rheumatol 20. https://doi.org/10.1002/acr2.11309

81.

Deane KD, Holers VM (2021) Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift. Arthritis Rheumatol 73:181–193CrossRef

82.

Masi AT (1983) Articular patterns in the early course of rheumatoid arthritis. Am J Med 75:16–26CrossRef

83.

Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361CrossRef

84.

Trouw LA, Huizinga TW, Toes RE (2013) Autoimmunity in rheumatoid arthritis: Different antigens—common principles. Ann Rheum Dis 72(Suppl 2):ii132–ii136

85.

Carubbi F, Alunno A, Gerli R, Giacomelli R (2019) Post-translational modifications of proteins: Novel insights in the autoimmune response in rheumatoid arthritis. Cells 8(7):657

86.

Grönwall C, Amara K, Hardt U, Krishnamurthy A, Steen J, Engstrom M et al (2017) Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis. J Autoimmun 84:29–45CrossRef

87.

Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I et al (2016) Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis 75:1099–1107CrossRef

88.

Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA et al (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 108:17372–17377CrossRef

89.

de Brito RS, Baldo DC, Andrade LEC (2019) Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol 59:2CrossRef

90.

Grönwall C, Liljefors L, Bang H, Hensvold AH, Hansson M, Mathsson-Alm L et al (2021) A comprehensive evaluation of the relationship between different IgG and IgA anti-modified protein autoantibodies in rheumatoid arthritis. Front Immunol 12:627986

91.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRef

92.

Van Hoovels L, Jacobs J, Vander Cruyssen B, Van den Bremt S, Verschueren P, Bossuyt X (2018) Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. Ann Rheum Dis 77:667–677CrossRef

93.

Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808CrossRef

94.

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281CrossRef

95.

Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163CrossRef

96.

van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949–R958CrossRef

97.

Derksen VF, Ajeganova S, Trouw LA, van der Helm-van Mil AH, Hafström I, Huizinga TW et al (2017) Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Ann Rheum Dis 76:716–720CrossRef

98.

Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I et al (2016) Identification of novel anti-acetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis 75:1099–1107CrossRef

99.

Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J et al (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis: a multi parameter prospective study. Arthritis Rheum 44:1736–1743CrossRef

100.

Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D et al (2007) The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis Rheum 56:2929–2935CrossRef

101.

Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ et al (2010) A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: Post hoc analyses from the BeSt study. Ann Rheum Dis 69:1333–1337CrossRef

102.

Jilani AA, Mackworth-Young CG (2015) The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. Int J Rheumatol 2015:728610. https://doi.org/10.1155/2015/728610CrossRef

103.

Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373:659–672CrossRef

104.

Jawaheer D, Thomson W, MacGregor AJ, Carthy D, Davidson J, Dyer PA et al (1994) Homozygosity for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum 37:681–686CrossRef

105.

Alarcon RT, Fernandes AR, Laurindo IM, Bértolo MB, Pinheiro GC, Andrade LE (2015) Characterization of cumulative joint damage patterns in patients with rheumatoid arthritis: a clinical, serological, and gene polymorphism perspective. J Rheumatol 42:405–412CrossRef

106.

Viatte S, Lee JC, Fu B, Espéli M, Lunt M, De Wolf JN et al (2016) Association between genetic variation in FOXO3 and reductions in inflammation and disease activity in inflammatory polyarthritis. Arthritis Rheumatol 68:2629–2636CrossRef

107.

Krabben A, Huizinga TW, Mil AH (2015) Biomarkers for radiographic progression in rheumatoid arthritis. Curr Pharm Des 21:147–169CrossRef

108.

Lee JC, Espéli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ et al (2013) Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155:57–69CrossRef

109.

van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 74:806–812CrossRef

110.

Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT (1985) When does rheumatoid disease start? Arthritis Rheum 28:485–489CrossRef

111.

Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749CrossRef

112.

Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386CrossRef

113.

Rakieh C, Nam JL, Hunt L, Hensor EM, Das S, Bissell LA et al (2015) Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis 74:1659–1666CrossRef

114.

Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE et al (2010) Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 69:490–494CrossRef

115.

Verheul MK, Böhringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW et al (2018) Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: Implications for very early identification of at-risk individuals. Arthritis Rheumatol 70:1721–1731CrossRef

116.

Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A et al (2012) Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis 71:1984–1990CrossRef

117.

Viatte S, Massey J, Bowes J, Duffus K, arcOGEN Consortium, Eyre S et al (2016) Replication of associations of genetic loci outside the HLA region with susceptibility to anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheumatol 68:1603–1613

118.

Källberg H, Ding B, Padyukov L, Bengtsson C, Rönnelid J, Klareskog L et al (2011) Smoking is a major preventable risk factor for rheumatoid arthritis: Estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 70:508–511CrossRef

119.

Bettner LF, Peterson RA, Bergstedt DT, Kelmenson LB, Demoruelle MK, Mikuls TR et al (2021) Combinations of anti-cyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years. ACR Open Rheumatol. https://doi.org/10.1002/acr2.11309CrossRef

120.

Jarlborg M, Courvoisier DS, Lamacchia C, Martinez-Prat L, Mahler M, Bentow C et al (2020) Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther 22:105CrossRef

121.

de Moel EC, Rech J, Mahler M, Roth J, Vogl T, Schouffoer A et al (2019) Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs. Arthritis Res Ther 21:268CrossRef

122.

Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J et al (2021) The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: Results from a collaboration of 16 registries. Rheumatology (Oxford) 60:820–828CrossRef

123.

Bird P, Hall S, Nash P, Connell CA, Kwok K, Witcombe D et al (2019) Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in phase III randomised clinical trials of tofacitinib. RMD Open 5:e000742

124.

Schlager L, Loiskandl M, Aletaha D, Radner H (2020) Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology (Oxford) 59:324–334CrossRef

125.

Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331CrossRef

126.

Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F et al (2015) Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74:1983–1989CrossRef

127.

Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum 42:1765–1772CrossRef

128.

Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H (2014) B-cell hyperactivity in primary Sjögren’s syndrome. Expert Rev Clin Immunol 10:483–499CrossRef

129.

Ramos-Casals M, Tzioufas AG, Font J (2005) Primary Sjögren’s syndrome: New clinical and therapeutic concepts. Ann Rheum Dis 64:347–354CrossRef

130.

Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T et al (2018) How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol 36(Suppl 112(3)):102–112

131.

Goules AV, Exarchos TP, Pezoulas VC, Kourou KD, Venetsanopoulou AI, De Vita S et al (2019) Sjögren’s syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts. Clin Exp Rheumatol 37(Suppl 118):175–184

132.

Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G (2015) Prediction of Sjögren’s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol 67:2427–2436CrossRef

133.

Andrade LE, Chan EK, Peebles CL, Tan EM (1996) Two major autoantigen-antibody systems of the mitotic spindle apparatus. Arthritis Rheum 39:1643–1653CrossRef

134.

Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76:9–16CrossRef

135.

Alspaugh MA, Talal N, Tan EM (1976) Differentiation and characterization of autoantibodies and their antigens in Sjögren’s syndrome. Arthritis Rheum 19:216–222CrossRef

136.

Wolin SL, Reinisch KM (2006) The Ro 60 kDa autoantigen comes into focus: Interpreting epitope mapping experiments on the basis of structure. Autoimmun Rev 5:367–372CrossRef

137.

Oke V, Wahren-Herlenius M (2012) The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 39:77–82CrossRef

138.

Mekinian A, Nicaise-Roland P, Chollet-Martin S, Fain O, Crestani B (2013) Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren’s syndrome in the absence of anti-SSA/SSB antibodies by ELISA. Rheumatology (Oxford) 52:2223–2228CrossRef

139.

Robbins A, Hentzien M, Toquet S, Didier K, Servettaz A, Pham BN et al (2019) Diagnostic utility of separate anti-Ro60 and anti-Ro52/TRIM21 antibody detection in autoimmune diseases. Front Immunol 10:444. https://doi.org/10.3389/fimmu.2019.00444CrossRef

140.

Ghillani P, André C, Toly C, Rouquette AM, Bengoufa D, Nicaise P et al (2011) Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: Results of a multicentric study. Autoimmun Rev 10:509–513CrossRef

141.

Retamozo S, Akasbi M, Brito-Zerón P, Bosch X, Bove A, Perez-de-Lis M et al (2012) Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren’s syndrome. Clin Exp Rheumatol 30:686–692

142.

Buvry C, Cassagnes L, Tekath M, Artigues M, Pereira B, Rieu V et al (2020) Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome. Respir Med 163:105895. https://doi.org/10.1016/j.rmed.2020.105895CrossRef

143.

Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L et al (2015) Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev 14:1019–1022CrossRef

144.

ter Borg EJ, Kelder JC (2014) Lower prevalence of extra-glandular manifestations and anti-SSB antibodies in patients with primary Sjögren’s syndrome and widespread pain: Evidence for a relatively benign subset. Clin Exp Rheumatol 32:349–353

145.

Baer AN, McAdams DeMarco M, Shiboski SC, Lam MY, Challacombe S, Daniels TE et al (2015) The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren’s syndrome. Ann Rheum Dis 74:1557–1561CrossRef

146.

Acar-Denizli N, Horváth IF, Mandl T, Priori R, Vissink A, Hernandez-Molina G et al (2020) Systemic phenotype related to primary Sjögren’s syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clin Exp Rheumatol 38(Suppl 126):85–94

147.

Baer AN, Medrano L, McAdams-DeMarco M, Gniadek TJ (2016) Association of anticentromere antibodies with more severe exocrine glandular dysfunction in Sjögren’s syndrome: Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken) 68:1554–1559CrossRef

148.

Ryu YS, Park SH, Lee J, Kwok SK, Ju JH, Kim HY et al (2013) Follow-up of primary Sjogren’s syndrome patients presenting positive anti-cyclic citrullinated peptides antibody. Rheumatol Int 33:1443–1446CrossRef

149.

Ramos-Casals M, Stone JH, Cid MC, Bosch X (2012) The cryoglobulinaemias. Lancet 379:348–360CrossRef

150.

La Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, Ferri C (1995) Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum 38:1859–1860CrossRef

151.

Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A et al (2016) Systemic activity and mortality in primary Sjögren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 75:348–355CrossRef

152.

Quartuccio L, Isola M, Baldini C, Priori R, Bocci EB, Carubbi F et al (2014) Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 51:75–80CrossRef

153.

Legatowicz-Koprowska M, Nitek S, Czerwińska J (2020) The complement system in primary Sjögren’s syndrome: The expression of certain cascade and regulatory proteins in labial salivary glands – observational study. Reumatologia 58:357–366CrossRef

154.

Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: Clinical and pathophysiologic aspects. Medicine (Baltimore) 88:284–293CrossRef

155.

Brito-Zerón P, Retamozo S, Gandía M, Akasbi M, Pérez-De-Lis M, Diaz-Lagares C et al (2012) Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun 39:43–48CrossRef

156.

Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685–1699CrossRef

157.

Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J (2008) Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 37:223–235CrossRef

158.

Medsger TA Jr (2003) Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 29:255–273CrossRef

159.

Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35–42CrossRef

160.

Kayser C, Fritzler MJ (2015) Autoantibodies in systemic sclerosis: Unanswered questions. Front Immunol 6:167CrossRef

161.

Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12:340–354CrossRef

162.

Sirotti S, Generali E, Ceribelli A, Isailovic N, De Santis M, Selmi C (2017) Personalized medicine in rheumatology: The paradigm of serum autoantibodies. Autoimmun Highlights 8:10CrossRef

163.

Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66:754–763CrossRef

164.

Hu PQ, Fertig N, Medsger TA Jr, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48:1363–1373CrossRef

165.

Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75–83CrossRef

166.

Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM (2015) Examination of autoantibody status and clinical features associated with cancer risk and cancer associated scleroderma. Arthritis Rheumatol 67:1053–1061CrossRef

167.

Roofeh D, Khanna D (2020) Management of systemic sclerosis: The first five years. Curr Opin Rheumatol 32:228–237CrossRef

168.

Saito A, Muro Y, Sugiura K, Akiyama M (2013) Low prevalence of autoantibodies to CENP-H, -I, -K, -L, -M, -N, -T and -U in a Japanese cohort of anti-centromere positive samples. Immunopharmacol Immunotoxicol 35:57–63CrossRef

169.

Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M et al (2015) Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis. Arthritis Rheumatol 67:3234–3244CrossRef

170.

Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ (1988) Development of connective tissue disease in patients presenting with Raynaud’s phenomenon: a six-year follow-up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 47:634–641CrossRef

171.

Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X (2007) Anti-centromere antibodies identify patients with Sjögren’s syndrome and autoimmune overlap syndrome. J Rheumatol 34:2253–2258

172.

Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T et al (2015) Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol 67:1045–1052CrossRef

173.

Lazzaroni MG, Cavazzana I, Colombo E, Dobrota R, Hernandez J, Hesselstrand R et al (2017) Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: Analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol 44:639–647CrossRef

174.

Phan TG, Cass A, Gillin A, Trew P, Fertig N, Sturgess A (1999) Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma. J Rheumatol 26:2489–2492

175.

Ceribelli A, Cavazzana I, Airo P, Franceschini F (2010) Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia (GAVE) in systemic sclerosis. J Rheumatol 37:1544CrossRef

176.

Sharif R, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H et al (2011) Anti-fibrillarin antibody in African American patients with systemic sclerosis: Immunogenetics, clinical features, and survival analysis. J Rheumatol 38:1622–1630CrossRef

177.

Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60:1112–1118CrossRef

178.

Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48:203–209CrossRef

179.

Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG et al (2006) Anti-Th/To-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 33:1600–1605

180.

Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M et al (2012) Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14:R50CrossRef

181.

Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr et al (2009) Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 61:958–965CrossRef

182.

Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: Correlation with characteristic clinical features. Arthritis Res Ther 13:R172CrossRef

183.

Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M (2015) Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 17:57CrossRef

184.

Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W et al (2016) Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: Clinical associations. Medicine (Baltimore) 95:e4713

185.

Fujii T, Mimori T, Akizuki M (1996) Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 39:1313–1318CrossRef

186.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRef

187.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407CrossRef

188.

Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F et al (2018) Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 75:1528–1537CrossRef

189.

Tanboon J, Uruha A, Stenzel W, Nishino I (2020) Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol 33:590–603CrossRef

190.

Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 54:50–63CrossRef

191.

Riddell V, Bagby S, McHugh N (2020) Myositis autoantibodies: recent perspectives. Curr Opin Rheumatol 32:548–552CrossRef

192.

Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL (2017) Comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52:1–19CrossRef

193.

Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367–371CrossRef

194.

Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60:116–123CrossRef

195.

Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP et al (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73:227–232CrossRef

196.

Mammen AL (2011) Autoimmune myopathies: Autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 7:343–354CrossRef

197.

Okiyama N (2021) Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med 10:1725CrossRef

198.

Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M et al (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513–522CrossRef

199.

Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P (2018) Bench to bedside review of myositis autoantibodies. Clin Mol Allergy 16:5–22CrossRef

200.

Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N et al (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 51:1278–1284CrossRef

201.

Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65:25–34CrossRef

202.

Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N (2007) Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 56:3132–3137CrossRef

203.

Basharat P, Christopher-Stine L (2015) Immune-mediated necrotizing myopathy: Update on diagnosis and management. Curr Rheumatol Rep 17:72CrossRef

204.

Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ et al (2013) Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann Neurol 73:397–407CrossRef

205.

Amlani A, Choi MY, Tarnopolsky M, Brady L, Clarke AE, Garcia-De La Torre I et al (2019) Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis. Front Immunol 10:745

206.

Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H et al (2016) Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 75:696–701CrossRef

207.

Rietveld A, Wienke J, Visser E, Vree Egberts W, Schlumberger W, van Engelen B et al (2021) Juvenile Dermatomyositis Research Group and the Dutch Myositis Consortium. Anti-Cytosolic 5'-nucleotidase 1A autoantibodies are absent in juvenile dermatomyositis. Arthritis Rheumatol 73:1329–1333

208.

European Association for the Study of the Liver (2015) EASL clinical practice guidelines: Autoimmune hepatitis. J Hepatol 63:971–1004CrossRef

209.

European Association for the Study of the Liver (2017) EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67:145–172CrossRef

210.

Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ et al (2009) Primary biliary cirrhosis. Hepatology 50:291–308CrossRef

211.

Manns MP, Lohse AW, Vergani D (2015) Autoimmune hepatitis – update 2015. J Hepatol 62:100–111CrossRef

212.

Sebode M, Weiler-Normann C, Liwinski T, Schramm C (2018) Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol 9:609CrossRef

213.

Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M et al (1997) Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 25:541–547CrossRef

214.

Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH et al (1987) Chronic active hepatitis associated with anti-liver/kidney microsome antibody type 1: a second type of autoimmune hepatitis. Hepatology 7:1333–1339CrossRef

215.

Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC (1988) Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8:1662–1666CrossRef

216.

Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S (2004) Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 38:801–804CrossRef

217.

Vergani D, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP et al (2004) Liver autoimmune serology: a consensus statement from the Committee for Autoimmune Serology of the International Autoimmune Hepatitis Group. J Hepatol 41:677–683CrossRef

218.

Frenzel C, Herkel J, Lüth S, Galle PR, Schramm C, Lohse AW (2006) Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 101:2731–2736CrossRef

219.

Liaskos C, Bogdanos DP, Davies ET, Dalekos GN (2007) Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol 60:107–108CrossRef

220.

Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U (2001) Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol 126:37–46CrossRef

221.

Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F (1988) Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 168:801–806CrossRef

222.

Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF (1989) Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 83:1066–1072CrossRef

223.

Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA (1988) Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85:8256–8260CrossRef

224.

Lapierre P, Hajoui O, Homberg JC, Alvarez F (1999) Formiminotransferase cyclo-deaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 116:643–649CrossRef

225.

Lenzi M, Manotti P, Muratori L, Cataleta M, Ballardini G, Cassani F et al (1995) Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 36:749–754CrossRef

226.

Kanzler S, Weidemann C, Gerken G, Löhr HF, Galle PR, zum Büschenfelde KHM et al (1999) Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 31:635–640

227.

Kirstein MM, Metzler F, Geiger E, Heinrich E, Hallensleben M, Manns MP et al (2015) Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 62:1524–1535CrossRef

228.

Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ (2012) Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 32:85–92CrossRef

229.

Rigopoulou EI, Roggenbuck D, Smyk DS, Liaskos C, Mytilinaiou MG, Feist E et al (2012) Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: Lost and found. Autoimmun Rev 12:260–269CrossRef

230.

Liberal R, Mieli-Vergani G, Vergani D (2013) Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmun 46:17–24CrossRef

231.

Selmi C, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G et al (2016) Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev 15:162–166CrossRef

232.

Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD et al (2012) Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 64:2319–2327CrossRef

233.

Agustinelli RA, Rodrigues SH, Mariz HA, Prado MS, Andrade LEC (2019) Distinctive features of positive anti-cell antibody tests (indirect immunofluorescence on HEp-2 cells) in patients with non-autoimmune diseases. Lupus 28:629–634CrossRef

234.

Keppeke GD, Nunes E, Ferraz ML, Silva EA, Granato C, Chan EK et al (2012) Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α. PLoS One 7:e45392

235.

Carcamo WC, Ceribelli A, Calise SJ, Krueger C, Chen L, Daves M et al (2013) Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients. J Clin Immunol 33:420–426CrossRef

236.

Calise SJ, Chan EKL (2020) Anti-rods/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery. Autoimmun Rev19:102643

237.

Desmet VJ, Gerber M, Hoofnaagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513–1520CrossRef

238.

Manns M, Gerken G, Kyriatsoulis A, Staritz M, zum Buschenfelde KHM (1987) Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1:292–294

239.

Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL et al (2002) Establishment of standardised SLA/LP immunoassays: Specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 51:259–264CrossRef

240.

Czaja AJ, Carpenter HA, Santrach PJ, Moore SB (1993) Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502–1507CrossRef

241.

O’Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ (2008) Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 48:550–556CrossRef

242.

Dinani AM, Fischer SE, Mosko J, Guindi M, Hirschfield GM (2012) Patients with autoimmune hepatitis who have antimitochondrial antibodies need longterm follow-up to detect late development of primary biliary cirrhosis. Clin Gastroenterol Hepatol 10:682–684CrossRef

243.

Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K et al (2007) Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. Hepatology 46:1436–1442CrossRef

244.

Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK et al (2007) Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 27:1226–1231CrossRef

245.

Corpechot C, Chazouilleres O, Poupon R (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55:1361–1367CrossRef

246.

Muratori P, Muratori L, Cassani F, Terlizzi P, Lenzi M, Rodrigo L et al (2002) Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 127:172–175CrossRef

247.

Andre C, Guillemin MC, Zhu J, Koken MH, Quignon F, Herve L et al (1996) The PML and PML/RARalpha domains: From autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 229:253–260CrossRef

248.

Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H (1997) Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 26:1123–1130

249.

Czaja AJ (2010) Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 55:2144–2161CrossRef

250.

Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M et al (2007) Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45:118–127CrossRef

251.

Sfakianaki O, Koulentaki M, Tzardi M, Tsangaridou E, Theodoropoulos PA, Castanas E et al (2010) Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients. World J Gastroenterol 16:4938–4943CrossRef

252.

Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP (2013) Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 37:572–585CrossRef

253.

Norman GL, Reig A, Viñas O, Mahler M, Wunsch E, Milkiewicz P et al (2019) The prevalence of anti-hexokinase-1 and anti-Kelch-like 12 peptide antibodies in patients with primary biliary cholangitis is similar in Europe and North America: a large international, multi-center study. Front Immunol 10:662CrossRef

254.

Chazouillères O (2015) Overlap syndromes. Dig Dis Basel Switz 33(Suppl 2):181–187CrossRef

255.

Silveira MG, Talwalkar JA, Angulo P, Lindor KD (2007) Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes. Am J Gastroenterol 102:1244–1250CrossRef

256.

Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R (1998) Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatol Baltim Md 28:296–301CrossRef

257.

Nguyen HH, Shaheen AA, Baeza N, Lytvyak F, Urbanski SJ, Mason AL et al (2018) Evaluation of classical and novel autoantibodies for the diagnosis of primary biliary cholangitis–autoimmune hepatitis overlap syndrome (PBC-AIH OS). PLoS One 13:e0193960

258.

Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R et al (2009) The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 104:1420–1425CrossRef

259.

Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F et al (2012) Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases. Can J Gastroenterol 26:125–129CrossRef

260.

Höftberger R (2015) Neuroimmunology: an expanding frontier in autoimmunity. Front Immunol 6:1–5CrossRef

261.

Flanagan EP (2019) Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases. Continuum (Minneap Minn) 25:815–844

262.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112CrossRef

263.

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189CrossRef

264.

Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J et al (2019) Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614–625CrossRef

265.

Reindl M, Jarius S, Rostasy K, Berger T (2017) Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? Curr Opin Neurol 30:295–301CrossRef

266.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J et al (2018) MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. Nervenarzt 89:1388–1399CrossRef

267.

dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K et al (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:1–10

268.

Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, De Haidar Jorge FM, Takahashi T et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474–481CrossRef

269.

Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89:900–908CrossRef

270.

López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP et al (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG–associated disorders. JAMA Neurol 75:1355–1363CrossRef

271.

Graus F, Saiz A, Dalmau J (2020) GAD antibodies in neurological disorders — insights and challenges. Nat Rev Neurol 16:353–365

272.

Ariño H, Höftberger R, Gresa-Arribas N, Martínez-Hernández E, Armangue T, Kruer MC et al (2015) Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol 72:1–8CrossRef

273.

Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, Bastiaansen AEM, Nagtzaam MMP, Hulsenboom ESP et al (2020) Neurologic syndromes related to anti-GAD65. Neurol Neuroimmunol Neuroinflammation 7:e696

274.

Dalmau J, Graus F (2018) Antibody-mediated encephalitis. N Engl J Med 378:840–851CrossRef

275.

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404CrossRef

276.

Van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PAE (2014) Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmun Rev 13:299–312CrossRef

277.

Linnoila JJ, Binnicker MJ, Majed M, Klein CJ, McKeon A (2016) CSF herpes virus and autoantibody profiles in the evaluation of encephalitis. Neurol Neuroimmunol NeuroInflammation 3:1–10CrossRef

278.

Danieli D, Moraes ACM, Alves MP, Dutra LA, Höftberger R, Barsottini OGP et al (2017) Anti-N-methyl-D-aspartate receptor encephalitis and Epstein-Barr virus: Another tale on autoimmunity? Eur J Neurol 24:e46–e47CrossRef

279.

Dutra LA, Abrantes F, Toso FF, Pedroso JL, Barsottini OGP, Hoftberger R (2018) Autoimmune encephalitis: a review of diagnosis and treatment. Arq Neuropsiquiatr 76:41–49

280.

Granerod J, Ambrose HE, Davies NWS, Clewley JP, Walsh AL, Morgan D et al (2010) Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 10:835–844CrossRef

281.

Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA (2012) The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis 54:899–904CrossRef

282.

Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165CrossRef

283.

Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA et al (2018) Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 83:166–177CrossRef

284.

Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D (2012) Extreme delta brush; a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79:1094–1100CrossRef

285.

Balu R, Mccracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ (2019) A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 92:e244–e252CrossRef

286.

Van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87:521–528CrossRef

287.

Vale TC, Pedroso JL, Dutra LA, Azevedo L, Filho LHP, Prado LBF et al (2017) Morvan syndrome as a paraneoplastic disorder of thymoma with anti-CASPR2 antibodies. Lancet 389:1367–1368CrossRef

288.

Lopez-Chiriboga AS, Komorowski L, Kümpfel T, Probst C, Hinson SR, Pittock SJ et al (2016) Metabotropic glutamate receptor type 1 autoimmunity. Neurology 86:1009–1013CrossRef

289.

Höftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind MD, Gelfand J et al (2015) Encephalitis and AMPA receptor antibodies. Neurology 84:2403–2412CrossRef

290.

Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E et al (2014) A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13:575–586CrossRef

291.

Gresa-Arribas N, Planagumà J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA et al (2016) Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology 86:2235–2242CrossRef

292.

Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Artigues MIB et al (2017) Investigations in GABA_A receptor antibody-associated encephalitis. Neurology 88:1012–1020CrossRef

293.

Hara M, Ariño H, Petit-Pedrol M, Sabater L, Titulaer MJ, Hernandez EM et al (2017) DPPX antibody-associated encephalitis main syndrome and antibody effects. Neurology 88:1340–1348CrossRef

294.

Höftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B et al (2013) Encephalitis and GABA_B receptor antibodies: Novel findings in a new case series of 20 patients. Neurology 81:1500–1506CrossRef

295.

Van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, De Bruijn MAAM et al (2016) Anti-LGI1 encephalitis. Neurology 87:1449–1456CrossRef

296.

Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J (2013) Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 70:1133–1139CrossRef

297.

Bizzaro N, Tozzoli R, Tonutti E, Piazza A, Manoni F, Ghirardello A et al (1998) Variability between methods to determine ANA, anti-dsDNA and anti-ENA auto antibodies: a collaborative study with the biomedical industry. J Immunol Methods 219:99–107CrossRef

298.

Pereira KM, Dellavance A, Andrade LE (2014) The challenge of identification of autoantibodies specific to systemic autoimmune rheumatic diseases in high throughput operation: Proposal of reliable and feasible strategies. J Immunol Methods 437:203–210

299.

Mummert E, Fritzler MJ, Sjowall C, Bentow C, Mahler M (2018) The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. J Immunol Methods 459:11–19

300.

Avrameas S (2016) Autopolyreactivity confers a holistic role in the immune system. Scand J Immunol 83:227–234CrossRef

301.

Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG (2013) Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 8:e60726

302.

Kemeny DM (1991) A practical guide to ELISA. Pergamon Press, Oxford, England

303.

Choi MY, Barber MR, Barber CE, Clarke AE, Fritzler MJ (2016) Preventing the development of SLE: Identifying risk factors and proposing pathways for clinical care. Lupus 25:838–849CrossRef

304.

Bossuyt X, Claessens J, Belmondo T, De Langhe E, Westhovens R, Poesen K et al (2019) Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios. Autoimmun Rev 18:102386

305.

Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ (1985) Antinuclear, anticytoplasmic, and anti-Sjögren’s syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 36:120–128CrossRef

306.

Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y et al (2004) Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892–900CrossRef

307.

Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG (2005) The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol 32:2144–2149

308.

Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM (1994) Autoantibodies in interstitial cystitis. J Urol 151:587–592CrossRef

309.

Ayaki M, Ohoguro N, Azuma N, Majima Y, Yata K, Ibaraki N et al (2002) Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmunity 35:319–327CrossRef

Titel: The Role of Autoantibody Testing in Modern Personalized Medicine
verfasst von: Cristiane Kayser
Lívia Almeida Dutra
Edgard Torres dos Reis-Neto
Charlles Heldan de Moura Castro
Marvin J. Fritzler
Luis Eduardo C. Andrade
Publikationsdatum: 04.03.2022
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2022
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-021-08918-6

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Role of Autoantibody Testing in Modern Personalized Medicine

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations

Antimitochondrial Antibodies: from Bench to Bedside

Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?

Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others

Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis

Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO